WallStreetZenWallStreetZen

NYSE: TEVA
Teva Pharmaceutical Industries Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TEVA

Based on 4 analysts offering 12 month price targets for Teva Pharmaceutical Industries Ltd

Min Forecast
$24.00-15.67%
Avg Forecast
$28.25-0.74%
Max Forecast
$35.00+22.98%

Should I buy or sell TEVA stock?

Based on 4 analysts offering ratings for Teva Pharmaceutical Industries Ltd.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their TEVA stock forecasts and price targets.

TEVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-05
lockedlocked$00.00+00.00%2025-11-06Find Out Why
lockedlocked$00.00+00.00%2025-09-24Find Out Why

1 of 1

Forecast return on equity

Is TEVA forecast to generate an efficient return?

Company
49.45%
Industry
216.74%
Market
342.02%
TEVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TEVA forecast to generate an efficient return on assets?

Company
8.99%
Industry
118.94%
TEVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TEVA earnings per share forecast

What is TEVA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$2.70+327.79%
Avg 2 year Forecast
$2.80+344.7%
Avg 3 year Forecast
$3.12+395.97%
TEVA's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

TEVA revenue forecast

What is TEVA's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$17.3B+3.29%
Avg 2 year Forecast
$17.4B+3.79%
Avg 3 year Forecast
$17.6B+5.13%
TEVA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TEVA earnings growth forecast

How is TEVA forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
113.58%
Industry
1,080.05%
Market
104.81%
TEVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
TEVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
TEVA's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

TEVA revenue growth forecast

How is TEVA forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
2.01%
Industry
281.86%
Market
58.59%
TEVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TEVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TEVA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
TEVA$28.46$28.25-0.74%Strong Buy
HLN$9.52N/AN/A
TAK$14.18N/AN/A
NBIX$155.51$177.86+14.37%Strong Buy
ZTS$118.65$170.75+43.91%Strong Buy
View Top Pharmaceutical Stocks

Teva Pharmaceutical Industries Stock Forecast FAQ

Is Teva Pharmaceutical Industries Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NYSE: TEVA) stock is to Strong Buy TEVA stock.

Out of 4 analysts, 3 (75%) are recommending TEVA as a Strong Buy, 1 (25%) are recommending TEVA as a Buy, 0 (0%) are recommending TEVA as a Hold, 0 (0%) are recommending TEVA as a Sell, and 0 (0%) are recommending TEVA as a Strong Sell.

If you're new to stock investing, here's how to buy Teva Pharmaceutical Industries stock.

What is TEVA's earnings growth forecast for 2025-2027?

(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual earnings growth rate of 113.58% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 1,080.05%, and while it is forecast to beat the US market's average forecast earnings growth rate of 104.81%.

Teva Pharmaceutical Industries's earnings in 2025 is $712,000,000.On average, 6 Wall Street analysts forecast TEVA's earnings for 2025 to be $3,092,041,098, with the lowest TEVA earnings forecast at $2,912,032,472, and the highest TEVA earnings forecast at $3,299,584,505. On average, 6 Wall Street analysts forecast TEVA's earnings for 2026 to be $3,214,226,686, with the lowest TEVA earnings forecast at $3,013,222,790, and the highest TEVA earnings forecast at $3,433,242,917.

In 2027, TEVA is forecast to generate $3,584,798,937 in earnings, with the lowest earnings forecast at $3,361,767,217 and the highest earnings forecast at $3,806,683,375.

What is TEVA's revenue growth forecast for 2025-2027?

(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 2.01% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 281.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.59%.

Teva Pharmaceutical Industries's revenue in 2025 is $16,776,000,000.On average, 7 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,880,111,367,936, with the lowest TEVA revenue forecast at $18,973,758,183,456, and the highest TEVA revenue forecast at $20,679,767,278,800. On average, 7 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,976,483,098,944, with the lowest TEVA revenue forecast at $19,000,145,681,232, and the highest TEVA revenue forecast at $20,842,681,395,504.

In 2027, TEVA is forecast to generate $20,233,474,381,632 in revenue, with the lowest revenue forecast at $18,976,052,748,480 and the highest revenue forecast at $21,186,866,149,104.

What is TEVA's forecast return on assets (ROA) for 2025-2027?

(NYSE: TEVA) forecast ROA is 8.99%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 118.94%.

What is TEVA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year TEVA price target, the average TEVA price target is $28.25, with the highest TEVA stock price forecast at $35.00 and the lowest TEVA stock price forecast at $24.00.

On average, Wall Street analysts predict that Teva Pharmaceutical Industries's share price could fall to $28.25 by Dec 5, 2026. The average Teva Pharmaceutical Industries stock price prediction forecasts a potential downside of 0.74% from the current TEVA share price of $28.46.

What is TEVA's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: TEVA) Teva Pharmaceutical Industries's current Earnings Per Share (EPS) is $0.63. On average, analysts forecast that TEVA's EPS will be $2.70 for 2025, with the lowest EPS forecast at $2.54, and the highest EPS forecast at $2.88. On average, analysts forecast that TEVA's EPS will be $2.80 for 2026, with the lowest EPS forecast at $2.63, and the highest EPS forecast at $2.99. In 2027, TEVA's EPS is forecast to hit $3.12 (min: $2.93, max: $3.32).

What is TEVA's forecast return on equity (ROE) for 2025-2027?

(NYSE: TEVA) forecast ROE is 49.45%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.